ASH1L (Absent, Small, or Homeotic-like 1) is a histone methyltransferase that plays a critical role in the epigenetic regulation of gene expression. It specifically catalyzes the methylation of lysine 36 on histone H3 (H3K36), a modification associated with the activation of gene transcription. ASH1L's activity is crucial for the proper development and differentiation of cells, as well as the maintenance of genomic stability. Through its role in histone modification, ASH1L influences a broad array of biological processes, including the regulation of developmental genes and the suppression of inappropriate gene expression. The precise modulation of ASH1L activity is essential for ensuring that genes are expressed at the right time and place, reflecting its importance in cellular and developmental biology.
The inhibition of ASH1L's enzymatic activity involves targeting the specific domains responsible for its interaction with histones and its methyltransferase function. Mechanisms of inhibition can include the disruption of the enzyme's substrate recognition, interference with its catalytic site, or hindrance of its ability to bind to chromatin. Inhibitors may act by mimicking the natural substrates of ASH1L, thereby competitively blocking access to the enzyme's active site. Alternatively, allosteric inhibitors may bind to regions of the enzyme other than the active site, inducing conformational changes that reduce its enzymatic activity. The development of ASH1L inhibitors is guided by a deep understanding of the protein's structure and the molecular dynamics of its interaction with histones. Such inhibitors could potentially serve as tools for studying the biological functions of ASH1L and the consequences of its inhibition on gene expression and cellular processes. Given ASH1L's involvement in critical regulatory pathways, the targeted inhibition of this enzyme presents a strategic approach to modulating epigenetic marks, with implications for understanding and potentially influencing the complex networks of gene regulation.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Epz004777 | 1338466-77-5 | sc-507560 | 100 mg | $575.00 | ||
EPZ004777 directly targets ASH1L by binding to its methyltransferase domain, effectively inhibiting its ability to methylate histone H3 at lysine 36. This inhibition disrupts the normal epigenetic regulation of gene expression, which is crucial for ASH1L's role in cellular processes. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 acts as a potent inhibitor of ASH1L by specifically interacting with its catalytic SET domain. This interaction prevents ASH1L from exerting its methyltransferase activity on histone H3, thereby inhibiting the epigenetic modifications that facilitate transcriptional activation. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
UNC0638 inhibits ASH1L by targeting and binding to the SET domain, responsible for its enzymatic activity of methylating histone H3 at lysine 36. This binding inhibits ASH1L's function, leading to alterations in gene expression patterns that are mediated by changes in the histone methylation landscape. |